1. Home
  2. LOCL vs MRKR Comparison

LOCL vs MRKR Comparison

Compare LOCL & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Local Bounti Corporation

LOCL

Local Bounti Corporation

HOLD

Current Price

$1.09

Market Cap

24.2M

ML Signal

HOLD

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.22

Market Cap

22.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOCL
MRKR
Founded
2021
1999
Country
United States
United States
Employees
286
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.2M
22.5M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
LOCL
MRKR
Price
$1.09
$1.22
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
13.9K
62.9K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.61
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$97.19
N/A
Revenue Next Year
$33.69
$936.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.98
$0.81
52 Week High
$4.00
$2.46

Technical Indicators

Market Signals
Indicator
LOCL
MRKR
Relative Strength Index (RSI) 28.72 36.50
Support Level $0.99 $1.17
Resistance Level $1.22 $1.54
Average True Range (ATR) 0.07 0.08
MACD -0.01 -0.03
Stochastic Oscillator 7.35 5.70

Price Performance

Historical Comparison
LOCL
MRKR

About LOCL Local Bounti Corporation

Local Bounti Corp is a controlled environment agriculture company. The business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides. The products of the company include living lettuce, leafy greens, herbs, and others.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

Share on Social Networks: